Strength of the association of anti-β2GP-I or lupus anticoagulant with APS by hematologic manifestation
| Hematological manifestation . | Clinical APS . | Nonclinical APS . | OR (95% CI) . | P . |
|---|---|---|---|---|
| Thrombocytopenia + Evans syndrome | n = 17 | n = 20 | ||
| LAC (−) | 5 | 13 | ||
| (29) | (65) | |||
| LAC (+) | 12 | 7 | 4.46 | .05 |
| (71) | (35) | (1.11-17.90) | ||
| n = 18 | n = 20 | |||
| Anti-β2GP-I (−) | 6 | 7 | ||
| IgG | (33) | (35) | ||
| n = 12 | n = 13 | 1.08 | NS* | |
| Anti-β2GP-I (+) | (66) | (65) | (0.28-4.13) | |
| IgG | ||||
| Hemolytic anemia + Evans syndrome | n = 7 | n = 11 | ||
| LAC (−) | 3 | 9 | ||
| (43) | (81) | — | ||
| LAC (+) | 4 | 2 | 2.25 | NS |
| (57) | (18) | (0.70-7.31) | ||
| n = 8 | n = 13 | |||
| Anti-β2GP-I (−) | 4 | 9 | ||
| IgG | (50) | (69) | — | |
| Anti-β2GP-I (+) | 4 | 4 | 4.56 | NS |
| IgG | (50) | (31) | (0.57-35.19) |
| Hematological manifestation . | Clinical APS . | Nonclinical APS . | OR (95% CI) . | P . |
|---|---|---|---|---|
| Thrombocytopenia + Evans syndrome | n = 17 | n = 20 | ||
| LAC (−) | 5 | 13 | ||
| (29) | (65) | |||
| LAC (+) | 12 | 7 | 4.46 | .05 |
| (71) | (35) | (1.11-17.90) | ||
| n = 18 | n = 20 | |||
| Anti-β2GP-I (−) | 6 | 7 | ||
| IgG | (33) | (35) | ||
| n = 12 | n = 13 | 1.08 | NS* | |
| Anti-β2GP-I (+) | (66) | (65) | (0.28-4.13) | |
| IgG | ||||
| Hemolytic anemia + Evans syndrome | n = 7 | n = 11 | ||
| LAC (−) | 3 | 9 | ||
| (43) | (81) | — | ||
| LAC (+) | 4 | 2 | 2.25 | NS |
| (57) | (18) | (0.70-7.31) | ||
| n = 8 | n = 13 | |||
| Anti-β2GP-I (−) | 4 | 9 | ||
| IgG | (50) | (69) | — | |
| Anti-β2GP-I (+) | 4 | 4 | 4.56 | NS |
| IgG | (50) | (31) | (0.57-35.19) |
Values are n (%).
APS indicates antiphospholipid syndrome; β2GP-I, β2-glycoprotein-I; CI, confidence interval; IgG, immunoglobulin G; IgA, immunoglobulin A; LAC, lupus anticoagulant test; NS, not significant; and OR, odds ratio.
Results with anti-β2GP-I of any isotype did not differ significantly.